

# **BLOOD AND BLOOD PRODUCTS USAGE IN CHILDREN RECEIVING CHEMOTHERAPY FOR CHILDHOOD CANCERS IN A NIGERIAN TERTIARY HEALTHCARE CENTRE.**

## **ABSTRACT**

### **Background**

Transfusion of blood remains an integral component in the supportive care of children with cancers. It is generally safe, and should be used liberally when necessary and available. In resource-poor settings however, the availability and usage of blood and its products is generally limited. This study is aimed at reviewing the usage of the various blood components amongst children receiving care in a paediatric cancer unit of a tertiary hospital, in Southern Nigeria.

**Methods:** A retrospective study on blood and blood product usage, in hospitalized paediatric cancer patients younger than 18 years old, over a two-year period, spanning from January 2022 to December 2023. Data were retrieved, entered into an excel sheet and analyzed. Results are presented using tables and figures.

**Results:** Of the 32 children treated for various cancers, 29 (90.63%), received at least one unit of blood transfusion before, during or in-between cycles of treatment. Patients less than 5 years of age were the most transfused group. Fresh whole blood was the most transfused component. Leucopenia, was the commonest indication for transfusion in these patients.

**Conclusion:** Most of the children admitted for cancers received blood transfusion at least once before, or in-between cycles of chemotherapy and/or surgery. The most common indications for transfusion of blood in order of decreasing frequency were leucopenia, anaemia and thrombocytopenia respectively.

**Keywords:** Children, cancers, blood, transfusion

## **INTRODUCTION**

Childhood cancers and other noncommunicable diseases are increasingly important causes of morbidity and death worldwide, especially in low and middle-income countries (LMIC).<sup>1</sup>Improvement in childhood cancer outcomes especially in these countries such as Nigeria require proper functioning health systems capable of early diagnosis and effective treatment of affected children.<sup>1,2</sup>Transfusion of blood and its products remains an essential component in the supportive care of children with cancers. It is generally safe, and should be used liberally when necessary and available.<sup>3-6</sup>Many reports from low-income countries have established that appropriate blood and blood products remain insufficient and limited in healthcare facilities of many sub-Saharan African settings and is unavailable for use when needed most.<sup>3-7</sup>

This study is aimed at reviewing the transfusion usage of the various blood components of childhood cancer patients in the Paediatric Oncology unit of a tertiary hospital, in Southern Nigeria.

## **METHODS**

A descriptive retrospective study reviewing the medical records of children less than 18 years of age, with cancers who received one or more units of blood or a blood product in the course of treatment for various cancers in the paediatric medical ward over a two-year period from January 2022 to December 2023 at the University of Uyo Teaching Hospital, Uyo, Akwa Ibom State, Southern Nigeria.

Information on the age, gender, cancer type diagnosis, as well as the blood component transfused were retrieved for each patient. The transfused blood in these children were obtained from related donors and few from non-related donors, but all were processed at the hospital's blood bank. Each unit of blood or blood product was screened for HIV, Syphilis, Hepatitis B and C. The haematological laboratory data reviewed was the complete blood count.

The decision to transfuse each child was based on the level of the various blood count parameters in addition to the clinical status of the patient and primary disease being managed. Transfusion episodes were considered as all blood transfusions a child received within one chemotherapy cycle period. Data retrieved was inputted to an excel sheet, and analyzed with the Microsoft Excel package. Variables were expressed in percentages, tables and figures. Descriptive statistics was also used.

## RESULTS

The total number of paediatric medical admissions in the study period, was 1031, and of these, 32 (3.1%) were children managed by the Paediatric Oncology unit for various cancers. The ages of these children ranged between 9 months and 16 years, with a median of 8 years. The Male:Female ratio was 0.8:1. Children older than 5 years of age, constituted more than two-thirds (71.9%) of the paediatric cancer admissions (Table 1).

Table 2 shows the range of various cancers confirmed on admission. The most frequently encountered cancer was neuroblastoma (10), which constituted 31.25% of the total paediatric cancer admissions. The transfusion history of the 32 children diagnosed with various cancers were evaluated. This showed that a greater percentage of these children (90.63%) needed a blood transfusion at one time or the other between treatment cycles with chemotherapy and/or surgery. They each received a minimum of one blood transfusion in the course of their admission at various cycles of drug treatment, with a maximum of five transfusions within a treatment cycle, the latter especially seen in children managed for acute lymphoblastic leukaemia.

Fresh whole blood was the most frequently transfused blood component (Figure 1). The commonest indication for its usage was leucopenia, coupled with evidence of infection. Total leucocyte counts before transfusion ranged from  $0.8 \times 10^9/L$  to  $85.7 \times 10^9/L$ . Neutropenia varied from severe to mild, with absolute neutrophil counts ranging between  $140/mm^3$  and  $3300/mm^3$ . Children five years of age and younger, were the most transfused group.

Figure 1 also shows that red cell transfusion, given as sedimented cells was the second most transfused blood component, while platelets and fresh frozen plasma were the least used components. The latter two blood products, together with granulocyte-colony stimulating factor were needed for use in the two children who were managed for acute lymphoblastic leukaemia. The haematocrit range before transfusion ranged between 11% - 35%, with a median of 21%. Platelet values ranged between  $9 \times 10^9/L$  and  $744 \times 10^9/L$ , with the most severe thrombocytopenia seen in children diagnosed with acute lymphoblastic leukaemia.

**Table 1: Age distribution of children with cancers**

<b>Age of children (Years)</b>	<b>N (%)</b>
< 1	1 (3.13)
1 - < 5	8 (25.00)
5 - < 10	10 (31.25)
10 - < 15	7 (21.87)
≥ 15	6 (18.75)
<b>TOTAL</b>	<b>32 (100)</b>

**Table 2: Frequency distribution of the various childhood cancers seen**

<b>TYPE OF CANCER</b>	<b>N (%)</b>
Nephroblastoma	10 (31.3)
Rhabdomyosarcoma	6 (18.8)
Non-Hodgkin's Lymphoma	2 (6.3)
Acute Lymphoblastic Leukaemia	2 (6.3)
Ovarian Tumour	2 (6.3)
Neuroblastoma	1 (3.1)
Retinoblastoma	1 (3.1)
Brain Tumour	1 (3.1)
Hodgkin's Lymphoma	1 (3.1)
Osteosarcoma	1 (3.1)
Ewing's Sarcoma	1 (3.1)

Synovial Sarcoma	1 (3.1)
Colon Carcinoma	1 (3.1)
Nasopharyngeal carcinoma	1 (3.1)
Pancreatoblastoma	1 (3.1)
<b>TOTAL</b>	<b>32 (100.0)</b>




Figure I: Distribution of various blood components transfused

1. Fresh Whole Blood- 58.8%
2. Sedimented cells – 23.5%
3. Platelet concenrate - 11.8%
4. Fresh frozen plasma (FFP) – 5.9%

## DISCUSSION

Transfusion of blood components remains a life-saving supportive practice in the care of children with hematologic and oncologic diseases. Some studies have documented, that pediatric oncology patients account for approximately 25% or greater of all inpatient paediatric transfusions in clinical practice, while others indicate a lower percentage.<sup>8,9,10</sup> Disease outcomes and long term survival in paediatric patients with cancers have improved significantly over the years due to advent of increasingly effective myelosuppressive chemotherapy regimens. Furthermore, the availability and effective usage of blood and its products have played a pivotal role in the delivery of supportive care that facilitates successful use and administration of these myelosuppressive regimens. Unfortunately, many centers in Nigeria and other sub-Saharan countries, still grapple with the challenge of unavailability of blood and blood components.<sup>3,7,11</sup>

In this present study, children older than 5 years of age, constituted more than two-thirds of the paediatric cancer admissions. This is in contrast with erstwhile studies from same study center, that reported younger-aged children as presenting more with childhood cancers.<sup>12,13</sup> It is also in contrast with other studies across many Nigerian centers that reported younger children under 5 years.<sup>11,14-17</sup> This present finding, could be attributed to the observation, that apart from nephroblastoma which had the highest presenting frequency, a wide distribution of childhood cancers in this study center within the stated period were those commoner in older children and adolescents like carcinomas, germ cell tumours and sarcomas. Other authors' reports seem to reflect more of the embryonal tumour types which commonly present earlier in life.<sup>11,14-16</sup>

Nephroblastoma as aforementioned, was the most frequent childhood cancer managed in the study period, and has remained the top-ranking cancer admission documented in the present study center for the past eight years.<sup>12,13</sup> Various studies on childhood cancers from different regions and centers in Nigeria and other countries have interestingly, observed differing trends of predominant childhood cancers seen.<sup>11-16</sup> There was no significant gender predilection in present study, which varies with documentation from northern Nigeria<sup>15</sup> and other regions that noted a male preponderance of the childhood cancers.<sup>11,16</sup>

A high frequency of children with cancers in this study received blood transfusion at least once or more, during their course of treatment. Studies from

various countries within and outside Africa, have also noted that the transfusion of a blood component is almost always necessary in the course of management of childhood cancers.<sup>5,8,9,11,18,19</sup> Children with cancer usually require blood or blood product support throughout their course of treatment. This may be due to the adverse effects of chemotherapy or radiotherapy on the blood cell lines, or as a result of surgery, and often as a consequence of the disease process itself.<sup>5</sup>

Of the available blood products, fresh whole blood was the most frequently used component in the course of treatment. The commonest indication for its usage was leucopenia, coupled with evidence of infection. A report from Enugu,<sup>9</sup> South-East Nigeria, also noted that children with malignancies and sepsis (infection) had the topmost indications for transfusion of blood, and mostly fresh whole blood used. Other researchers documented other blood products, like red cell concentrate or sedimented cells as more frequently used.<sup>6-8</sup> In many sub-Saharan African (sSA) countries, whole blood is said to be more commonly available from blood transfusion services than red cell concentrates.<sup>6</sup> This is still applauding however, the significant progress many countries have made in the implementation of component preparation, despite unique issues faced. Such challenges as quality assurance, low donation, high demand, cost-limitations to component preparation and leucocyte-reduction.<sup>3,5-8</sup>

Cellular blood components including viable lymphocytes also need to be irradiated in children with cancer. The gamma irradiation prevents T-lymphocytes from proliferating and reduces the risk of transfusion-associated graft-versus-host disease (TA-GVHD).<sup>5</sup> This is unavailable presently in the study center and many centers across Nigeria.<sup>11,20</sup>

The second most frequently used blood product in these children, was the red cell concentrate (transfused as sedimented cells). It was used in children with haematocrit less than 30%, also considering their clinical status and primary disease, to build up their haemoglobin concentration before commencement of treatment, either chemotherapy or surgery. This is a standard operating procedure maintained in the paediatric haematology unit of the study center. Anaemia frequently occurs in children with cancers, due to the suppression or dysfunction of erythropoiesis secondary to the underlying disease, as well as a consequence of bleeding which can also occur in these children.<sup>5</sup> National audits of paediatric red blood cell transfusions in the United Kingdom reported that more than half of paediatric transfusions were given to haematology/oncology patients.<sup>5</sup>

Platelet concentrate was also available, though sparingly in present study. The difficulties in getting multiple donors for the pooling of platelets constituted a barrier to easy availability. The use of fresh whole blood was sometimes used as a substitute, for the prescription of platelets where availability of platelets would constitute a delay in treatment- prophylactic or therapeutic. This reaffirms the importance and need for greater advocacy/implementation of blood component availability for use in many resource-poor settings.<sup>5-8</sup> The unavailability of cold centrifuges in many Nigerian centers caring for children with cancers, also constitutes a barrier to availability of platelets.<sup>11</sup> It is however, available in this study center. In other studies, children with malignancies were top ranked in the need and use of platelet concentrates, and they were transfused mostly as prophylaxis or sometimes therapeutically to increase low platelet counts and decrease the risk of bleeding.<sup>6</sup>

Thrombocytopenia occurs frequently in many children diagnosed with various cancers, at one time or the other in the course of their illness. It could result from bone marrow infiltration by the tumour cells, or could be chemotherapy induced or associated with other morbidities such as sepsis or disseminated intravascular coagulopathy.<sup>5</sup> Dosing recommendation is 10 to 15 mL/kg of ideal body weight. Leucoreduction and irradiation are also recommended for platelet transfusions in paediatric cancer patients. This is unavailable presently in study centre.<sup>5,20</sup>

Fresh Frozen Plasma (FFP) is transfused to correct multiple coagulation factor deficiencies in patients with active bleeding (therapeutic transfusions) or to prevent bleeding before invasive procedures (prophylactic transfusions). Dosing recommendation is 10 to 20 mL/kg.<sup>5,20</sup> Patients with cancer may be at risk for abnormalities of haemostasis due to the tumor pathology, evolution of the disease as well as treatment effects. In present study, it was used in children with severe myelosuppression, overwhelming infection and bleeding from multiple sites. While FFP transfusion has its benefits, it also has some risks that should be weighed against its perceived benefit.<sup>5</sup> Its usage in the few children as indicated, gave satisfactory transfusion outcome.

## **CONCLUSION**

Transfusion of at least one component of blood or more, was seen to be necessary for almost every child admitted for the treatment of childhood cancers. Fresh whole blood was the most used component in this study center. This makes it imperative that blood and its products should always be

available, safe and accessible in every center caring for children with cancers, to optimize their care, outcome of treatment and survival.

## REFERENCES

1. Force LM, Abdollahpour I, Advani SM, Agius D, Ahmadian E et al. The global burden in childhood and adolescent cancer in 2017: an analysis of the global burden of disease study 2017. *Lancet Oncol* 2019; 1211-25.
2. Sloan FK, Gelband H. Cancer control opportunities in low- and middle-income countries. Committee on cancer control in low and middle-income countries, board on global health. The National Academic Press, 2007. Available from <http://www.nap.edu> (Accessed 20/7/2024).
3. Custer B, Zou S, Glynn SA, Makani J, Tayou Tagny C, El Ekiaby M et al. Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop. *Transfusion*. 2018; 58 (5): 1307–1317. doi: 10.1111/trf.14598.
4. Pranata CJ, Suryawan N, Prihatni D. Transfusion reactions in pediatric patients. *Althea Medical journal*. 2020;7(4): DOI 10.15850.
5. Dilek GG. Principles of transfusion in children with cancer. *Hematology, transfusion and cell therapy*: 2021; 43(s3) s12-s13.
6. Uyoaga S, Maitland K. Use of whole blood as the routine transfusion product in Africa. *ISBT Science series* 2019;14(1); 1-8.
7. Hassell O, Bates I, Maitland K: Blood Transfusion in Resource-Limited Settings. In: Clancy N (ed): *Hunter's Tropical Medicine*. 9th edition. London: Magill– Maguire– Ryan Solomon; 2012: 162–167.
8. Al-Saqladi AM, Albanna TA. A Study of Blood Transfusion in Pediatric Patients at a Teaching Hospital, Aden, Yemen. *Int J Clin Trans Med*. 2021; 9: 1-9.

9. Ughasoro MD, Ikefuna AN, Emodi IJ, Ibeziako SN, Nwose SO. Audit of blood transfusion practices in the paediatric medical ward of a Tertiary Hospital in Southeast Nigeria. *East Afr Med J.* 2013;90 (1):5–11.
10. Ino-Ekanem, MB, **Bassey, EU.** Overview of blood transfusion in a Paediatric medical setting of a tertiary hospital in south-south Nigeria. *Int Health Sci Res.* 2016; 6(7):47-51.
11. Akinsete AM, Odugbemi BA, Ogundowole GE, Anene-Nzelu UU, Temiye E. Paediatric Oncology in Nigeria: A Panoramic view. *JCO. Global Oncology* 2019;5:1-7.
12. Bassey EU, Udo EN. Childhood cancers in a tertiary facility in southern Nigeria: a four-year update. *Int J Res Med Sc* 2022; 10(5):1012-1015.
13. Bassey EU, Akpan IA, Nnoli C, Akpan EE. Challenges in the management of childhood cancer patients in a tertiary hospital in southern Nigeria. *Asian J Med Health* 2022;20:(10):103-108.
14. Nlemadim AS, Akaba KO, Ekanem IA, Nkanga ED, Ugbem TI et al. Incidence, Treatment and Outcomes of childhood cancers in Calabar. *Niger J Med* 2023; 32(5):473-79.
15. Mohammed A, Aliyu HO. Childhood cancers in a referral hospital in northern Nigeria. *Indian J Med Pediatr Oncol* 2009; 30(3):95-98.
16. Eke GK, Ugwueze N, Akani NA. Childhood cancers in a Tertiary Centre, southern Nigeria: Spectrum and Outcome of treatment. *J Cancer Tumour Int.* 2021; 11(1):25-34.
17. Arewa OP. One year clinical audit of the use of blood and blood components at a tertiary hospital in Nigeria *Niger J Clin Pract* 2009;12(4):429-433.

18. Stevenson J, DeGroot NP, Keller F, Brock KE, Bergsagel DJ et al. Characteristics and outcomes of pediatric oncology patients at risk for guardians declining transfusion of blood components. *Cancer Rep (Hoboken)*. 2023 Jan; 6(1): e1665.
19. Nellis ME, Goel R, Karam O. Transfusion Management in Pediatric Oncology Patients. *Haematol Oncol Clin North Am*. 2019;33(5):903-13.
20. Transfusion of blood components in paediatric age groups: an evidence-based practice guideline adapted for the use in Egypt using 'Adapted ADAPTE'. *Annals Haematol*. 2024; 103: 173-1388.

UNDER PEER REVIEW